Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALNY
  • CUSIP: 02043Q10
  • Web:
  • Market Cap: $5.67 billion
  • Outstanding Shares: 86,190,000
Average Prices:
  • 50 Day Moving Avg: $57.45
  • 200 Day Moving Avg: $48.37
  • 52 Week Range: $31.38 - $80.11
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.19
  • P/E Growth: -0.28
Sales & Book Value:
  • Annual Revenue: $58.77 million
  • Price / Sales: 96.50
  • Book Value: $9.65 per share
  • Price / Book: 6.82
  • EBIDTA: ($407,540,000.00)
  • Net Margins: -869.63%
  • Return on Equity: -37.25%
  • Return on Assets: -30.67%
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 9.14%
  • Quick Ratio: 9.14%
  • Average Volume: 1.10 million shs.
  • Beta: 2.69
  • Short Ratio: 12.01

Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings data on Friday, May, 5th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.22) by $0.03. The company had revenue of $19 million for the quarter, compared to analysts' expectations of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The firm's quarterly revenue was up 160.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.21) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When will Alnylam Pharmaceuticals make its next earnings announcement?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Alnylam Pharmaceuticals.

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?

17 brokerages have issued 1 year target prices for Alnylam Pharmaceuticals' shares. Their predictions range from $36.00 to $116.00. On average, they anticipate Alnylam Pharmaceuticals' stock price to reach $72.53 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.

What are analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • 1. Chardan Capital analysts commented, "We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space." (11/30/2016)
  • 2. According to Zacks Investment Research, "Alnylam is a development-stage biopharmaceutical company focused on the development of RNAi-based therapeutics. The company expects to achieve the profile of three marketed products by the end of 2020. Investor focus should be on the company's progress with its late-stage pipeline candidate, patisiran. Meanwhile, Alnylam’s RNAi technology has allowed the company to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals will not only provide it with funds but also take its RNAi technology outside the core focus area. Estimate movement has been mixed lately ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters. However, the discontinuation of the phase III ENDEAVOUR study on revusiran, following the Data Monitoring Committee’s recommendation (DMC) is disappointing." (10/25/2016)
  • 3. Needham & Company LLC analysts commented, "Alnylam announced additional data from its ongoing fitusiran Phase 1/2 trial in Hemophilia. Emerging safety and efficacy profile is consistent w/ prior clinical data and point to a differentiated once-monthly agent. Phase 3 initiation, however, has been pushed into 2017 (was 2H16). Regulators are seeking additional information around dose. Mgmt expects to complete dose-escalation in Hemophilia pts w/ Inhibitors later this yr." (7/25/2016)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.00%), Wellington Management Group LLP (0.00%), Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), Baillie Gifford & Co. (0.00%) and State Street Corp (2.51%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Legal & General Group Plc, State Street Corp, TimesSquare Capital Management LLC, Morgan Stanley, UBS Group AG, First Trust Advisors LP, Frontier Capital Management Co. LLC and State of Wisconsin Investment Board. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, John Maraganore, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Rockefeller Financial Services Inc., Blue Ridge Capital L.L.C., Pictet Asset Management Ltd., Russell Investments Group Ltd., Vanguard Group Inc. and Janus Capital Management LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alnylam Pharmaceuticals stock cost?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $65.80.

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (?)
Ratings Breakdown: 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $72.53 (10.23% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017Piper Jaffray CompaniesSet Price TargetBuy$116.00LowView Rating Details
5/17/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$75.00 -> $80.00MediumView Rating Details
5/17/2017Goldman Sachs Group IncReiterated RatingNeutral$44.00 -> $64.00MediumView Rating Details
5/17/2017Credit Suisse Group AGReiterated RatingOutperform$50.00 -> $90.00MediumView Rating Details
5/17/2017Leerink SwannReiterated RatingMarket Perform$53.00 -> $67.00HighView Rating Details
5/17/2017Cowen and CompanyReiterated RatingOutperform$100.00LowView Rating Details
5/15/2017Chardan CapitalLower Price TargetBuy$110.00 -> $95.00HighView Rating Details
5/8/2017Morgan StanleyBoost Price TargetEqual Weight$39.00 -> $42.00LowView Rating Details
4/17/2017BMO Capital MarketsInitiated CoverageOutperform$73.00MediumView Rating Details
3/20/2017FBR & CoReiterated RatingBuyHighView Rating Details
2/9/2017Needham & Company LLCReiterated RatingBuy$98.00 -> $68.00N/AView Rating Details
2/3/2017JMP SecuritiesSet Price TargetBuy$69.00N/AView Rating Details
12/1/2016Jefferies Group LLCSet Price TargetBuy$58.00N/AView Rating Details
11/3/2016Barclays PLCReiterated RatingHold$50.00N/AView Rating Details
10/6/2016Stifel NicolausLower Price TargetHold$68.00 -> $36.00N/AView Rating Details
10/6/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$83.00 -> $51.00N/AView Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$74.00N/AView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldN/AView Rating Details
6/24/2015Deutsche Bank AGSet Price TargetBuy$155.00N/AView Rating Details
6/24/2015Canaccord GenuityReiterated RatingBuy$160.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
2017 EPS Consensus Estimate: ($5.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.30)($1.33)
Q2 20172($1.36)($1.30)($1.33)
Q3 20172($1.36)($1.21)($1.29)
Q4 20172($1.37)($1.19)($1.28)
(Data provided by Zacks Investment Research)


Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 88.70%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.00View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.00View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.00View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.35View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateHeadline logoCommit To Buy Alnylam Pharmaceuticals At $50, Earn 18% Annualized Using Options - Nasdaq - May 26 at 8:47 PM logo$21.7 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (ALNY) This Quarter - May 26 at 5:18 PM logo Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $21.7 Million - May 26 at 4:10 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) EVP Sells $825,000.00 in Stock - May 25 at 7:24 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) PT Set at $116.00 by Piper Jaffray Companies - May 25 at 6:04 PM logoAlnylam Pharma (ALNY) Announces 5M Share Common Offering - May 25 at 3:54 PM logoAlnylam Pharmaceuticals Prices Public Offering of Common Stock - May 25 at 3:53 PM logoAlnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline - May 25 at 3:53 PM logoRegeneron Presents Positive Phase II Data on HoFH Candidate - May 25 at 3:53 PM logoAlnylam Pharmaceuticals Prices Public Offering of Common Stock - Business Wire (press release) - May 24 at 3:25 PM logo Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) to Post -$1.23 EPS - May 24 at 1:26 PM logoAlnylam Pharma (ALNY) Announces 5M Share Common Offering - - May 24 at 7:48 AM logoAlnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock - May 24 at 7:48 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Given Consensus Recommendation of "Buy" by Brokerages - May 23 at 4:16 PM logoLeerink Swann Comments on Alnylam Pharmaceuticals, Inc.'s FY2018 Earnings (ALNY) - May 18 at 2:48 PM logoAkshay Vaishnaw Sells 43,750 Shares of Alnylam Pharmaceuticals, Inc. (ALNY) Stock - May 17 at 10:29 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Given a $80.00 Price Target by Ladenburg Thalmann Financial Services Analysts - May 17 at 8:32 PM logoMichael Mason Sells 9,375 Shares of Alnylam Pharmaceuticals, Inc. (ALNY) Stock - May 17 at 7:47 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Goldman Sachs Group Inc - May 17 at 2:08 PM logoCredit Suisse Group AG Reaffirms Outperform Rating for Alnylam Pharmaceuticals, Inc. (ALNY) - May 17 at 1:32 PM logoAlnylam Pharmaceuticals Reaches Analyst Target Price - May 17 at 12:30 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Earns Market Perform Rating from Leerink Swann - May 17 at 12:16 PM logoAlnylam Pharmaceuticals' (ALNY) "Outperform" Rating Reaffirmed at Cowen and Company - May 17 at 10:20 AM logoAlnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3% - May 16 at 3:30 PM logoWhy Ionis Results Today Support A Pair Trade With Alnylam - Benzinga - May 16 at 7:23 AM logoWhy Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today - Motley Fool - May 16 at 7:23 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Lowered to "Buy" at Vetr Inc. - May 16 at 12:34 AM logoWhy Ionis Results Today Support A Pair Trade With Alnylam - May 15 at 3:28 PM logoWhy Ionis Results Today Support A Pair Trade With Alnylam - May 15 at 3:28 PM logoHow Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial - May 15 at 3:28 PM logoHow Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial - May 15 at 3:28 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Given a $118.00 Price Target at Piper Jaffray Companies - May 15 at 2:34 PM logoChardan Capital Raises Alnylam Pharmaceuticals, Inc. (ALNY) Price Target to $110.00 - May 15 at 11:26 AM logoAlnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer - May 12 at 9:01 PM logoAlnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO - Motley Fool - May 12 at 4:00 PM logoAlnylam to Webcast Presentations at Upcoming May Investor Conferences - May 12 at 1:46 AM logoETFs with exposure to Alnylam Pharmaceuticals, Inc. : May 11, 2017 - May 11 at 8:45 PM logoAlnylam to Webcast Presentations at Upcoming May Investor ... - Business Wire (press release) - May 11 at 1:41 AM logoEdited Transcript of ALNY earnings conference call or presentation 5-May-17 12:30pm GMT - May 10 at 8:39 PM logoAlnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO - May 10 at 4:29 PM logoCFO Moves: Alnylam Pharmaceuticals - Wall Street Journal (subscription) (blog) - May 10 at 9:25 AM logoBRIEF-Alnylam Pharmaceuticals appoints Manmeet Soni as chief financial officer - Reuters - May 9 at 3:27 PM logoAlnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 3:27 PM logoAlnylam Expands Leadership Team with Multiple Experienced Biotech Leaders - May 9 at 9:20 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Earns "Hold" Rating from Credit Suisse Group AG - May 9 at 7:38 AM logoAlnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y - Nasdaq - May 8 at 3:25 PM logoAlnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y - May 8 at 3:25 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Morgan Stanley - May 8 at 1:22 PM logoAlnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 6 at 3:55 PM logoChardan Capital Reiterates Buy Rating for Alnylam Pharmaceuticals, Inc. (ALNY) - May 5 at 10:50 PM



Alnylam Pharmaceuticals (ALNY) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff